Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Massimo De Siena"'
Autor:
Lucio Taranto, Roberto Minici, Giuseppe Mazzarella, Massimo De Siena, Francesco Manti, Maria Petullà, Domenico Laganà
Publikováno v:
Journal of Radiological Review. 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::67df135d5ff1e2988446b9e793c6d6ae
https://doi.org/10.23736/s2283-8376.18.00087-6
https://doi.org/10.23736/s2283-8376.18.00087-6
Autor:
Sebastiano Di Salvo, Nicola Perrotti, Carmine Talarico, Mariaconcetta Reale, Grazia Pavia, Massimo De Siena, Tiziana Gravina, Anna Artese, Francesca Giancotti, Giorgio Settimo Barreca, Stefano Alcaro, Nadia Marascio, Isabella Romeo, Fernanda Fabiani, Alfredo Focà, Vito Marano, Carlo Torti, Maria Carla Liberto
Publikováno v:
Journal of medical virology. 90(7)
We report a real-life 3D therapy failure in a patient treated with ombitasvir (OMV)/paritaprevir/ritonavir and dasabuvir without ribavirin (3D-R). He had therapy failure at week 12 after the end of treatment. We detected resistance-associated substit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6792c1a57ca3a87ee0159b90913637d0
https://pubmed.ncbi.nlm.nih.gov/29575060
https://pubmed.ncbi.nlm.nih.gov/29575060
Autor:
Claudio, Carallo, Antonio, Loprete, Giuseppe, Mazza, Giovanni, Bellotti, Massimo, de Siena, Pietro, Serrao, Elisa Stella, Vuoto, Maria Serena, de Franceschi, Concetta, Irace, Agostino, Gnasso
Publikováno v:
Clinical hemorheology and microcirculation. 60(3)
Heparin-induced Extracorporeal Low Density Lipoprotein Precipitation (HELP) Apheresis gives beneficial reductions in Low Density Lipoprotein (LDL) cholesterol levels; otherwise, extracorporeal circulation settings might elicit inflammation and platel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ed5537dacbd4238adf961831f35c99b
https://pubmed.ncbi.nlm.nih.gov/24787628
https://pubmed.ncbi.nlm.nih.gov/24787628
Autor:
Antonio Ascione, null CLEO Study Group, Luigi Elio Adinolfi, Pietro Amoroso, Angelo Andriulli, Orlando Armignacco, Tiziana Ascione, Sergio Babudieri, Giorgio Barbarini, Michele Brogna, Francesco Cesario, Vincenzo Citro, Ernesto Claar, Raffaele Cozzolongo, Giuseppe D’Adamo, Emilio D’Amico, Pellegrino Dattolo, Massimo De Luca, Vincenzo De Maria, Massimo De Siena, Giuseppe De Vita, Antonio Di Giacomo, Rosanna De Marco, Giorgio De Stefano, Giulio De Stefano, Sebastiano Di Salvo, Raffaele Di Sarno, Nunzia Farella, Laura Felicioni, Basilio Fimiani, Luca Fontanella, Giuseppe Foti, Caterina Furlan, Francesca Giancotti, Giancarlo Giolitto, Tiziana Gravina, Barbara Guerrera, Roberto Gulminetti, Angelo Iacobellis, Michele Imparato, Angelo Iodice, Vincenzo Iovinella, Antonio Izzi, Alfonso Liberti, Pietro Leo, Gennaro Lettieri, Ileana Luppino, Aldo Marrone, Ettore Mazzoni, Vincenzo Messina, Roberto Monarca, Vincenzo Narciso, Lorenzo Nosotti, Adriano Maria Pellicelli, Alessandro Perrella, Guido Piai, Antonio Picardi, Paola Pierri, Grazia Pietromatera, Francesco Resta, Luca Rinaldi, Mario Romano, Angelo Rossini, Maurizio Russello, Grazia Russo, Rodolfo Sacco, Vincenzo Sangiovanni, Antonio Schiano, Antonio Sciambra, Gaetano Scifo, Filomena Simeone, Annarita Sullo, Pierluigi Tarquini, Paolo Tundo, Alfredo Vallone
Publikováno v:
World Journal of Hepatology. 8:949
AIM:To check the safety and efficacy of boceprevir/telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d28bc99042ad82c395e2080c1e67a32
https://doi.org/10.4254/wjh.v8.i22.949
https://doi.org/10.4254/wjh.v8.i22.949